TLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Telix Pharmaceuticals Ltd (TLX) shows positive momentum in the pre-market due to FDA acceptance of its TLX101-Px imaging agent application, but the lack of strong technical buy signals, neutral trading sentiment, and limited financial data suggest it is not an optimal buy for a beginner investor seeking long-term growth. Holding is recommended until further clarity on financial performance or stronger buy signals emerges.
The MACD is positive and expanding, indicating upward momentum. RSI is at 73.54, which is approaching overbought territory but still neutral. Moving averages are converging, showing no clear trend. Key resistance levels are at 10.059 and 9.799, with the pre-market price at 10.66 already above these levels.
Positive analyst upgrades and increased price targets from Citi and RBC Capital. Pre-market price surge of 8.78%.
Stock trend analysis suggests potential short-term declines (-0.93% next day, -5.15% next week, -14.29% next month). Neutral trading sentiment from hedge funds and insiders. No recent congress trading data.
No financial data available for analysis.
Citi and RBC Capital maintain a Buy rating, with Citi increasing the price target to $22.50 and RBC citing a compelling risk/reward profile. Analysts are optimistic about the company's prospects, particularly with the FDA submission for TLX101-Px.
